Health Care & Life Sciences » Biotechnology | Halozyme Therapeutics Inc.

Halozyme Therapeutics Inc. | Cash Flow

Fiscal year is January-December. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Net Income before Extraordinaries
83,478.60
68,375.00
32,231.00
103,023.00
62,971.00
80,330
Depreciation, Depletion & Amortization
1,226.90
1,762.00
1,677.00
2,410.00
2,161.00
2,388
Other Funds
10,809.50
18,989.00
22,968.00
33,252.00
48,233.00
34,308
Funds from Operations
71,442.10
47,624.00
7,586.00
67,361.00
113,365.00
43,634
Changes in Working Capital
22,202.70
106.00
29,497.00
16,978.00
20,688.00
5,866
Net Operating Cash Flow
49,239.50
47,518.00
37,083.00
50,383.00
134,053.00
49,500
Capital Expenditures
2,297.50
1,368.00
2,360.00
3,137.00
1,350.00
Purchase/Sale of Investments
45,571.60
31,583.00
8,248.00
73,629.00
162,382.00
Net Investing Cash Flow
47,869.10
32,951.00
5,888.00
76,766.00
163,732.00
Issuance/Reduction of Debt, Net
19,985.30
-
-
148,756.00
15,995.00
Net Financing Cash Flow
25,064.30
114,501.00
13,098.00
150,621.00
131,655.00
Net Change in Cash
72,044.30
34,032.00
18,097.00
23,472.00
101,976.00
Free Cash Flow
51,537.00
48,886.00
39,443.00
53,520.00
132,703.00
Change in Capital Stock
5,079.00
114,501.00
13,098.00
1,865.00
147,650.00

About Halozyme Therapeutics

View Profile
Address
11388 Sorrento Valley Road
San Diego California 92121
United States
Employees -
Website http://www.halozyme.com
Updated 07/08/2019
Halozyme Therapeutics, Inc. is a biopharmaceutical company specializes in research, development, and commercialization of human enzymes and other drug candidates. It focuses on novel oncology therapies that target the tumor microenvironment. Its products include PEGPH20, HTI-1511, PEG-ADA2, and HYLENEX recombinant.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.